KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Given Average Rating of "Buy" by Analysts

Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) have received a consensus recommendation of "Buy" from the eight analysts that are presently covering the company, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $24.83.

A number of equities research analysts have recently issued reports on the stock. Needham & Company LLC reaffirmed a "buy" rating and issued a $28.00 target price on shares of KalVista Pharmaceuticals in a report on Tuesday, April 8th. Jones Trading restated a "buy" rating and set a $30.00 price objective on shares of KalVista Pharmaceuticals in a report on Wednesday, March 26th. Citizens Jmp raised shares of KalVista Pharmaceuticals to a "strong-buy" rating in a research report on Friday, January 31st. JMP Securities began coverage on shares of KalVista Pharmaceuticals in a research report on Friday, January 31st. They issued an "outperform" rating and a $19.00 price target for the company. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $20.00 price objective on shares of KalVista Pharmaceuticals in a report on Friday, March 14th.

Insiders Place Their Bets

In other KalVista Pharmaceuticals news, major shareholder Venrock Healthcare Capital Par acquired 100,000 shares of the business's stock in a transaction that occurred on Wednesday, February 12th. The stock was bought at an average cost of $9.23 per share, with a total value of $923,000.00. Following the acquisition, the insider now owns 5,217,285 shares in the company, valued at approximately $48,155,540.55. This represents a 1.95 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Benjamin L. Palleiko sold 6,669 shares of KalVista Pharmaceuticals stock in a transaction on Friday, March 7th. The shares were sold at an average price of $11.97, for a total value of $79,827.93. Following the completion of the transaction, the chief executive officer now owns 287,811 shares of the company's stock, valued at approximately $3,445,097.67. This trade represents a 2.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have bought 129,137 shares of company stock valued at $1,196,312 and have sold 17,292 shares valued at $184,625. Insiders own 10.50% of the company's stock.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Large investors have recently added to or reduced their stakes in the business. Aquatic Capital Management LLC purchased a new stake in KalVista Pharmaceuticals in the 4th quarter worth approximately $44,000. Earned Wealth Advisors LLC bought a new position in KalVista Pharmaceuticals in the first quarter worth about $44,000. GAMMA Investing LLC boosted its position in shares of KalVista Pharmaceuticals by 567.3% during the first quarter. GAMMA Investing LLC now owns 4,431 shares of the specialty pharmaceutical company's stock valued at $51,000 after purchasing an additional 3,767 shares in the last quarter. CWM LLC grew its position in shares of KalVista Pharmaceuticals by 12,636.1% in the 1st quarter. CWM LLC now owns 4,585 shares of the specialty pharmaceutical company's stock worth $53,000 after buying an additional 4,549 shares during the period. Finally, Tower Research Capital LLC TRC grew its holdings in KalVista Pharmaceuticals by 666.9% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company's stock worth $54,000 after purchasing an additional 5,502 shares during the period.

KalVista Pharmaceuticals Stock Down 2.4 %

NASDAQ KALV opened at $11.90 on Friday. The firm's 50 day moving average is $12.04 and its 200-day moving average is $10.42. KalVista Pharmaceuticals has a 12-month low of $7.30 and a 12-month high of $15.50. The company has a market capitalization of $591.62 million, a PE ratio of -3.27 and a beta of 0.05.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.